Inhibition of Toll-like Receptor 4 Using Small Molecule, TAK-242, Protects Islets from Innate Immune Responses

Area of Science:

• Immunology
• Endocrinology
• Transplantation

Background:

• Type 1 and type 3c diabetes involve loss of pancreatic beta-cell mass.
• Islet transplantation is a therapeutic strategy to restore beta-cell function.
• Innate immune responses, including instant blood-mediated inflammatory reactions and monocyte activation, contribute to transplanted islet loss.

Purpose of the Study:

• To investigate the role of toll-like receptor 4 (TLR4) in innate inflammatory responses following islet transplantation.
• To evaluate the efficacy of targeting TLR4 to mitigate islet damage and immune cell activation.

Main Methods:

• Assessment of plasma biomarkers (miR-375, miR-200c) to evaluate graft function loss.
• In vitro models to study the effects of TLR4 inhibition on islet cells and immune cells.
• Utilizing TAK-242, a TLR4 inhibitor, in peritransplant models.

Main Results:

• Graft function loss was observed shortly after transplantation, indicated by biomarker changes.
• Targeting TLR4 with TAK-242 demonstrated mitigation of islet damage in vitro.
• TAK-242 reduced immune cell activation during the peritransplant period.

Conclusions:

• Toll-like receptor 4 (TLR4) inhibition is a viable strategy to reduce innate immune responses and inflammation after islet transplantation.
• TAK-242 shows potential as a therapeutic agent to improve outcomes for islet transplantation.
• Targeting TLR4 may enhance the long-term success of islet grafts in diabetic patients.